Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ ... (uccessfully with Evotec we have decided ...)

Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million

Date:2/14/2008

uccessfully with Evotec, we have decided to extend the term of our agreement. We remain impressed by Evotec's breadth of drug discovery expertise coupled with their knowledge of CNS diseases that ideally complement our efforts in the search for novel treatments that may slow or prevent Huntington's Disease," commented Dr Robert Pacifici, Chief Scientific Adviser to CHDI.

"We are extremely proud that CHDI, an organization dedicated solely to Huntington's Disease research, has chosen us as their partner in one of the largest collaborations a not-for-profit organization has signed with a biotechnology company," said Dr Mark Ashton, Executive Vice President Business Development Services at Evotec. "This collaboration is an excellent example for how our integrated drug discovery and CNS expertise adds value to companies with no or little internal discovery infrastructure. Working together, Evotec and CHDI have the tools in place to rapidly discover novel drugs against Huntington's Disease targets."

Forward looking statements

Information set forth in this report contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Evotec's products and services, the amount and timing of payments that Evotec may receive under its collaboration agreement with CHDI, the anticipated timing and results of Evotec's clinical and pre-clinical programs, and other statements that are not historical facts. Evotec cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information as a result of risks and uncertainties. These include risks and uncertainties relating to: Evotec's ability to complete the merger because conditions to the closing of the merger may not be satisfied; the failure to successfully int
'/>"/>

1

GOOD

Page: 1 2 3 4
Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. Evotec Reports Third Quarter 2007 Results
6. Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board
7. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
8. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
9. Roche Extends Tender Offer for Ventana
10. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
11. NASA Extends Cooperative Agreement With NSBRI

Post Your Comments:

Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ ...(uccessfully with Evotec we have decided ...)